Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Mattingly G, Weilser RH, Young J, Adeyi B, Dirks B, Babcock T, Lasser R, Scheckner, B, Goodman, D BioMed Central Psychiatry BMC Psychiatry 2013, 13:39
Background
Despite the overall high degree of response to pharmacotherapy, consensus is lacking on how to judge clinical response or define optimal treatment/remission when treating adults with attention-deficit/hyperactivity disorder (ADHD). This study examined clinical response and symptomatic remission in analyses of 2 studies of lisdexamfetamine dimesylate (LDX) in adults with ADHD.
